Nice article about epigenetics in cancer research.  Article mentions some of the competitors in trials, including Gilead, Incyte, GSK, AbbVie and Zenith and the tumor types they are targeting.   This whole topic of epigenetic mechanisms is gaining more and more credibility as top researchers and companies keep finding new and interesting results.

It seems that thrombocytopenia (low blood platelet count) occurs at different dosing levels with many of these in Phase I/II trials.

Zenith is mentioned as being in I/II trial with enzalutamide but not much more info. 

You may need to register (free) to view the entire article. 

https://www.onclive.com/publications/oncology-live/2018/vol-19-no-12/bet-inhibitors-form-a-growing-area-of-epigenetic-cancer-research 

masila